652 related articles for article (PubMed ID: 16987835)
1. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
Selenko-Gebauer N; Duschek N; Minimair G; Stingl G; Karlhofer F
Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii45-8. PubMed ID: 16987835
[TBL] [Abstract][Full Text] [Related]
2. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study.
Nguyen VA; Eisendle K; Gruber I; Hugl B; Reider D; Reider N
Rheumatology (Oxford); 2010 Mar; 49(3):583-7. PubMed ID: 20040526
[TBL] [Abstract][Full Text] [Related]
3. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of bosentan in the treatment of Raynaud's phenomenon in patients with systemic sclerosis never treated with prostanoids.
Parisi S; Bruzzone M; Centanaro Di Vittorio C; Laganà A; Peroni CL; Fusaro E
Reumatismo; 2014 Mar; 65(6):286-91. PubMed ID: 24705032
[TBL] [Abstract][Full Text] [Related]
5. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
6. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.
Korn JH; Mayes M; Matucci Cerinic M; Rainisio M; Pope J; Hachulla E; Rich E; Carpentier P; Molitor J; Seibold JR; Hsu V; Guillevin L; Chatterjee S; Peter HH; Coppock J; Herrick A; Merkel PA; Simms R; Denton CP; Furst D; Nguyen N; Gaitonde M; Black C
Arthritis Rheum; 2004 Dec; 50(12):3985-93. PubMed ID: 15593188
[TBL] [Abstract][Full Text] [Related]
7. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
[TBL] [Abstract][Full Text] [Related]
8. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
Colakoğlu M; Cobankara V; Akpolat T
Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
[TBL] [Abstract][Full Text] [Related]
9. Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis.
Hettema ME; Zhang D; Bootsma H; Kallenberg CG
Ann Rheum Dis; 2007 Oct; 66(10):1398-9. PubMed ID: 17881663
[No Abstract] [Full Text] [Related]
10. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
Serri J; Legré R; Veit V; Guardia C; Gay AM
Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
[TBL] [Abstract][Full Text] [Related]
11. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
[TBL] [Abstract][Full Text] [Related]
12. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis.
Gardinali M; Pozzi MR; Bernareggi M; Montani N; Allevi E; Catena L; Cugno M; Bottasso B; Stabilini R
J Rheumatol; 2001 Apr; 28(4):786-94. PubMed ID: 11327251
[TBL] [Abstract][Full Text] [Related]
14. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study.
Sambo P; Amico D; Giacomelli R; Matucci-Cerinic M; Salsano F; Valentini G; Gabrielli A
J Rheumatol; 2001 Oct; 28(10):2257-62. PubMed ID: 11669166
[TBL] [Abstract][Full Text] [Related]
15. Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon.
Moore TL; Vail A; Herrick AL
Rheumatology (Oxford); 2007 Feb; 46(2):363-4. PubMed ID: 17116656
[No Abstract] [Full Text] [Related]
16. Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension.
Rosato E; Molinaro I; Borghese F; Rossi C; Pisarri S; Salsano F
J Rheumatol; 2010 Dec; 37(12):2531-9. PubMed ID: 20810512
[TBL] [Abstract][Full Text] [Related]
17. Seasonal variation of Raynaud's phenomenon secondary to systemic sclerosis.
Watson HR; Robb R; Belcher G; Belch JJ
J Rheumatol; 1999 Aug; 26(8):1734-7. PubMed ID: 10451070
[TBL] [Abstract][Full Text] [Related]
18. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis.
Herrick AL; van den Hoogen F; Gabrielli A; Tamimi N; Reid C; O'Connell D; Vázquez-Abad MD; Denton CP
Arthritis Rheum; 2011 Mar; 63(3):775-82. PubMed ID: 21360507
[TBL] [Abstract][Full Text] [Related]
19. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.
Dziadzio M; Denton CP; Smith R; Howell K; Blann A; Bowers E; Black CM
Arthritis Rheum; 1999 Dec; 42(12):2646-55. PubMed ID: 10616013
[TBL] [Abstract][Full Text] [Related]
20. Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis.
Cestelli V; Manfredi A; Sebastiani M; Praino E; Cannarile F; Giuggioli D; Ferri C
Mod Rheumatol; 2017 Jan; 27(1):110-114. PubMed ID: 27310203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]